Suppr超能文献

哌甲酯增效疗法在难治性强迫症治疗中的作用:病例系列

Role of Methylphenidate Augmentation in Treatment-Resistant Obsessive-Compulsive Disorder: A Case Series.

作者信息

Mudgal Varchasvi, Mishra Saloni, Gupta Upma, Bagul Koustubh R

机构信息

Psychiatry, Mahatma Gandhi Memorial Medical College, Indore, IND.

Physiology, Netaji Subhash Chandra Bose Medical College, Jabalpur, Jabalpur, IND.

出版信息

Cureus. 2025 May 31;17(5):e85131. doi: 10.7759/cureus.85131. eCollection 2025 May.

Abstract

Background Treatment-resistant obsessive-compulsive disorder (tr-OCD) remains a significant clinical challenge, as many patients fail to respond to conventional serotonergic therapies despite multiple augmentation strategies. Emerging evidence from neurobiological research suggests that dopaminergic dysfunction, particularly in the prefrontal cortex, may contribute to the persistence of OCD symptoms. The objective of this study was to evaluate the efficacy and tolerability of methylphenidate (MPH), a dopamine and norepinephrine reuptake inhibitor, as an adjunct in patients with tr-OCD. Methodology This case series examines six individuals with tr-OCD who remained symptomatic despite adequate trials of first-line selective serotonin reuptake inhibitors (SSRIs) and various augmentation strategies. MPH was introduced as an adjunct to their existing pharmacotherapy regimens. Clinical outcomes were assessed using the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) at baseline and during follow-up over several weeks, with additional clinical judgment supporting therapeutic decisions. Results All six patients demonstrated significant clinical improvement following MPH augmentation. The mean baseline Y-BOCS score was 27.4, which reduced to a mean post-treatment score of 15.1, representing a mean reduction of 12.3 points. Reductions in obsessive thoughts and compulsive behaviors were observed, alongside improvements in cognitive flexibility and impulse control. The treatment was generally well-tolerated, with no serious adverse effects reported. Conclusion These preliminary findings suggest that dopaminergic augmentation with MPH may offer therapeutic benefits in cases of tr-OCD. The observed improvements support the hypothesis that enhancing prefrontal dopamine availability can positively influence OCD symptomatology. Further randomized controlled trials are necessary to confirm these results, define optimal dosing strategies, and establish long-term safety and efficacy.

摘要

背景

难治性强迫症(tr-OCD)仍然是一项重大的临床挑战,因为尽管采取了多种增效策略,但许多患者对传统的血清素能疗法没有反应。神经生物学研究的新证据表明,多巴胺能功能障碍,尤其是前额叶皮质的功能障碍,可能导致强迫症症状持续存在。本研究的目的是评估哌醋甲酯(MPH),一种多巴胺和去甲肾上腺素再摄取抑制剂,作为tr-OCD患者辅助治疗的疗效和耐受性。

方法

本病例系列研究了6例tr-OCD患者,尽管他们接受了充分的一线选择性5-羟色胺再摄取抑制剂(SSRIs)试验和各种增效策略,但仍有症状。MPH被引入作为他们现有药物治疗方案的辅助药物。在基线和数周的随访期间,使用耶鲁-布朗强迫症量表(Y-BOCS)评估临床结果,并通过额外的临床判断支持治疗决策。

结果

所有6例患者在MPH增效治疗后均表现出显著的临床改善。Y-BOCS评分的平均基线值为27.4,治疗后平均降至15.1,平均降低了12.3分。观察到强迫观念和强迫行为减少,同时认知灵活性和冲动控制得到改善。该治疗总体耐受性良好,未报告严重不良反应。

结论

这些初步研究结果表明,MPH进行多巴胺能增效治疗可能对tr-OCD患者有益。观察到的改善支持了这样的假设,即提高前额叶多巴胺水平可以对强迫症症状产生积极影响。需要进一步的随机对照试验来证实这些结果,确定最佳给药策略,并确立长期安全性和疗效。

相似文献

1
Role of Methylphenidate Augmentation in Treatment-Resistant Obsessive-Compulsive Disorder: A Case Series.
Cureus. 2025 May 31;17(5):e85131. doi: 10.7759/cureus.85131. eCollection 2025 May.
3
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Mol Psychiatry. 2006 Jul;11(7):622-32. doi: 10.1038/sj.mp.4001823. Epub 2006 Apr 4.
5
Second-generation antipsychotics for obsessive compulsive disorder.
Cochrane Database Syst Rev. 2010 Dec 8(12):CD008141. doi: 10.1002/14651858.CD008141.pub2.
6
Systematic Review and Meta-Analysis: Early Treatment Responses of Selective Serotonin Reuptake Inhibitors and Clomipramine in Pediatric Obsessive-Compulsive Disorder.
J Am Acad Child Adolesc Psychiatry. 2016 Oct;55(10):851-859.e2. doi: 10.1016/j.jaac.2016.07.768. Epub 2016 Aug 4.
7
Summary of the comparative effectiveness review on off-label use of atypical antipsychotics.
J Manag Care Pharm. 2012 Jun;18(5 Suppl B):S1-20. doi: 10.18553/jmcp.2012.18.S5-B.1.
8
Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD).
Cochrane Database Syst Rev. 2008 Jan 23;2008(1):CD001765. doi: 10.1002/14651858.CD001765.pub3.
9
Efficacy and tolerability of vortioxetine monotherapy in SSRI-resistant OCD: a retrospective multicenter study.
Front Psychiatry. 2025 Jun 13;16:1617345. doi: 10.3389/fpsyt.2025.1617345. eCollection 2025.
10
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.

本文引用的文献

1
A Meta-analysis of Transcranial Magnetic Stimulation in Obsessive-Compulsive Disorder.
Biol Psychiatry Cogn Neurosci Neuroimaging. 2023 Nov;8(11):1145-1155. doi: 10.1016/j.bpsc.2023.06.003. Epub 2023 Jun 19.
2
Treatment-resistant OCD: Pharmacotherapies in adults.
Compr Psychiatry. 2023 Jan;120:152352. doi: 10.1016/j.comppsych.2022.152352. Epub 2022 Oct 25.
3
Methylphenidate for attention-deficit/hyperactivity disorder in adults: a narrative review.
Psychopharmacology (Berl). 2021 Oct;238(10):2667-2691. doi: 10.1007/s00213-021-05946-0. Epub 2021 Aug 26.
4
Case Report: Treatment of a Comorbid Attention Deficit Hyperactivity Disorder and Obsessive-Compulsive Disorder With Psychostimulants.
Front Psychiatry. 2021 May 12;12:649833. doi: 10.3389/fpsyt.2021.649833. eCollection 2021.
5
Pharmacotherapeutic Strategies and New Targets in OCD.
Curr Top Behav Neurosci. 2021;49:331-384. doi: 10.1007/7854_2020_204.
6
Pharmacotherapy for Treatment-Resistant Obsessive-Compulsive Disorder.
J Clin Psychiatry. 2020 Sep 8;81(5):19ac13182. doi: 10.4088/JCP.19ac13182.
9
Promising Treatments for Obsessive-Compulsive Disorder: A Call for Additional Research.
Curr Med Chem. 2018;25(41):5690-5697. doi: 10.2174/0929867324666170526120916.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验